More about
Familial Hyperlipidemia
Clinical Guidance
Lipid Management
Treatment Approaches
PCSK9 Inhibitors
Clinical Guidance
Lipid Management
Cardiovascular Disease Prevention
Primary Prevention- LDL-C ≥190 mg/dL
Clinical Guidance
Lipid Management
Cardiovascular Disease Prevention
Secondary Prevention- Clinical ASCVD
Clinical Guidance
Lipid Management
Lipid and Lipoprotein Basics
Secondary Hyperlipidemia
Clinical Guidance
Lipid Management
Lipid and Lipoprotein Basics
Familial Hyperlipidemias
News
September 23, 2022
2 min read
Save
‘Similar strategy’ needed for global CVD prevention in men, women: PURE
The magnitude of associations with major CVD for most risk factors are similar in women and men, despite sex differences in risk factor levels, according to an analysis of the PURE study.
News
October 14, 2019
3 min read
Save
Lp(a) has strong effect on CVD risk
CHICAGO — Lipoprotein(a) has been shown to be an independent, causal and genetic risk factor for CVD, with higher prevalence in patients of African, South Asian, Asian and Oceanic ancestry, according to a presentation at the Cardiometabolic Health Congress.